TREVENA INC - TRVN STOCK NEWS

Trevena, Inc. (Nasdaq:TRVN) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 12-14, 2022, in New York. The company's corporate overview presentation is scheduled for September 12 at 4:30 PM ET. A webcast link will be available on Trevena's investor website, with a replay accessible for 30 days post-event. Trevena focuses on developing innovative medicines for CNS disorders, with an approved product, OLINVYK, for acute pain management, and a promising pipeline that includes candidates for diabetic neuropathic pain, migraine, and opioid use disorder.

Trevena, Inc. (Nasdaq: TRVN) announced its second-quarter 2022 results, reporting a net loss of $15 million, with a cash balance of $49.5 million sufficient to fund operations into mid-2023. The company continues positive engagement in launching OLINVYK, having signed a multi-year agreement with Vizient for broader access. Recent data showed OLINVYK significantly reduces neurocognitive impairment compared to IV morphine. Additionally, the Phase 1 study of TRV045 for diabetic neuropathic pain is on track, with completion expected in 2H 2022.

Trevena, Inc. (Nasdaq: TRVN) announced the closing of a registered direct offering, raising $2 million through the sale of 1,800 shares of Series A convertible preferred stock and 200 shares of Series B preferred stock, along with warrants for 8 million shares of common stock. The preferred shares are convertible into 8 million common shares at a price of $0.25 each. A special meeting of stockholders is planned to vote on a reverse stock split, which requires shareholder approval. Proceeds will fund general corporate purposes.

Trevena, Inc. (Nasdaq: TRVN) announced a registered direct offering, securing $2 million from a healthcare-focused investor through the sale of 1,800 shares of Series A preferred stock and 200 shares of Series B preferred stock, along with warrants for 8 million common shares. Each preferred share has a stated value of $1,000 and a conversion price of $0.25. The funds raised will be used for general corporate purposes. The company plans to seek stockholder approval for a reverse stock split, with voting rights assigned to the preferred shares. The offering is expected to close around July 29, 2022.

Trevena, Inc. (Nasdaq: TRVN) announced positive results in its cognitive function study of OLINVYK, showing a significant reduction in sedation compared to IV morphine. Additionally, a contract was secured with a purchasing organization, enhancing drug access. The company is on track to complete Phase 1 trials of TRV045 for diabetic neuropathic pain by 2H 2022. Financially, Trevena has implemented cost reductions to extend its cash runway to mid-2023, with approximately $49.5 million in cash and equivalents as of June 30, 2022.

Trevena, Inc. (Nasdaq: TRVN) announced a publication in the Expert Review of Neurotherapeutics regarding OLINVYK (oliceridine), an intravenous opioid analgesic. The review, conducted by Dr. Eugene R. Viscusi, highlights the efficacy and safety of OLINVYK, which was studied in over 1,500 patients with moderate-to-severe acute pain. Approved by the FDA in August 2020, OLINVYK is indicated for adults requiring IV opioid analgesics when alternative treatments are inadequate. The company emphasizes the clinical significance of responder rates from the pivotal Phase 3 APOLLO trials.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical firm specializing in CNS disorders, announced participation by President & CEO Carrie Bourdow and CMO Mark Demitrack in a fireside chat at the JMP Securities Life Sciences Conference on June 15-16, 2022. The chat is scheduled for 10:00am ET on June 15. A webcast link will be available online.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, will have Carrie Bourdow (President & CEO) and Barry Shin (CFO) participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. Their presentation is scheduled for May 24, 2022, from 11:30 am to 12:00 pm ET. Trevena focuses on innovative medicines for CNS disorders, with OLINVYK® (oliceridine) as their approved product and a pipeline including TRV045, TRV250, and TRV734 for various indications. Interested participants can register through the HCW events website.

Trevena, Inc. (TRVN) reported Q1 2022 results, highlighting progress in its commercialization strategy for OLINVYK and ongoing clinical studies. The company initiated a refocused strategy in mid-February, resulting in 2,500 customer interactions, primarily in critical care. OLINVYK showed reduced respiratory impact compared to IV morphine in elderly subjects. Trevena closed a $40 million financing agreement, receiving $15 million in April. The net loss for Q1 was $16.4 million, with cash reserves projected to fund operations into 2023. A conference call was held on May 11, 2022.